Abstract
Structural modifications of the neuronal calcium channel blocker MONIRO-1, including constraining the phenoxyaniline portion of the molecule and replacing the guanidinium functionality with tertiary amines, led to compounds with significantly improved affinities for the endogenously expressed CaV2.2 channel in the SH-SY5Y neuroblastoma cell line. These analogues also showed promising activity towards the CaV3.2 channel, recombinantly expressed in HEK293T cells. Both of these ion channels have received attention as likely targets for the treatment of neuropathic pain. The dibenzoazepine and dihydrobenzodiazepine derivatives prepared in this study show an encouraging combination of neuronal calcium ion channel inhibitory potency, plasma stability and potential to cross the blood–brain-barrier.
| Original language | English |
|---|---|
| Article number | 115655 |
| Number of pages | 10 |
| Journal | Bioorganic & Medicinal Chemistry |
| Volume | 28 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - 15 Sept 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Benzodiazepine
- Ca2.2
- Ca3.2
- N-type calcium channel
- Pain
- T-type calcium channel
Fingerprint
Dive into the research topics of 'The neuronal calcium ion channel activity of constrained analogues of MONIRO-1'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver